By using machine learning techniques to scour electronic health records, researchers have identified individuals who were likely to have binge eating disorder (BED) but had not received a formal diagnosis. Genomewide association studies including such patients enabled the investigators to identify several risk variants that were correlated with BED irrespective of body mass index (BMI), which covaries with BED and is a potential confounding factor. Read More
A new drug that inhibits the glutamate carboxypeptidase II (GCPII) enzyme could be used to treat inflammatory bowel disease (IBD), according to a new study in mice and human organoids. After decades of research trying to design GCPII inhibitors against neurological disorders, the new compound could be effective for another use. Read More
Immpact Bio USA Inc. has received FDA clearance of its IND application for IMPT-514, a bispecific CD19/CD20 chimeric antigen receptor (CAR) T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE). Read More
Origenis GmbH has described cyclin-dependent kinase 9 (CDK9) inhibitors, particularly CDK9/cyclin T1, reported to be useful for the treatment of cancer, viral infections, obesity and more. Read More
Monoclonal antibodies targeting PD-1/PD-L1 have shown promising antitumor efficacy. However, their clinical use is limited by several drawbacks. Read More
Ibio Inc. has announced promising in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage. Read More
Dicot AB has received clearance from the Swedish Medical Products Agency to begin a first-in-human trial with LIB-01, a potency agent to treat erectile dysfunction and premature ejaculation. Read More
Bakx Therapeutics Inc. and Ipsen Pharma SA have disclosed apoptosis regulator BAX activators reported to be useful for the treatment of cancer. Read More
Cytomed Therapeutics Ltd. has signed a memorandum of understanding (MOU) with Hangzhou CNK Therapeutics Co. Ltd. allowing Cytomed to utilize CNK's Piggybac technology to permanently graft the chimeric antigen receptor (CAR) gene into its γδ T cells via a non-viral gene editing method. Read More
Biogen Inc. has synthesized 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis (MS). Read More
Sichuan Good Doctor Panxi Pharmaceutical Co. Ltd. has identified polypeptides reported to be useful for the treatment of inflammatory bowel disease, ulcerative colitis, and dysbacteriosis. Read More
Leukemic cells rely on excessive mitochondrial respiratory and energy metabolism. Therefore, targeting mitochondrial proteases has been proposed as a potential approach to improve therapeutic regimens for acute myeloid leukemia (AML). The mitochondrial caseinolytic protease P (ClpP), located in the mitochondrial matrix, maintains protein quality by mediating the proteolytic hydrolysis of damaged proteins. The chaperone ClpX regulates this hydrolysis and is overexpressed in AML, thus providing a rationale for using ClpP agonists to disrupt AML proliferation. Read More
Researchers at 3D Medicines (Beijing) Co. Ltd. and 3D Medicines Inc. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer. Read More
